健民集團(600976.SH):簽訂三份技術開發合同
格隆匯9月28日丨健民集團(600976.SH)公佈,公司與南京恆道醫藥科技有限公司簽訂《技術開發合同》,委託其進行JMEY-AX12 項目的技術開發,技術委託開發服務費用450萬元;
公司與湖北麗益醫藥科技有限公司簽訂《技術開發合同》,委託其進行JMEY-KL13項目的技術開發,技術委託開發服務費用450萬元;
公司與山東百諾醫藥股份有限公司簽訂《技術開發合同》,委託其進行JMEY-PT14項目的技術開發,技術委託開發服務費用420萬元;
公司此次委託開發事項不存在關聯交易。
公司擬開發的JMEY-AX12、JMEY-KL13、JMEY-PT14等藥品研發項目,有利於補充公司藥品品種,豐富公司的產品線。公司與第三方簽訂技術開發合同,有利於擴大公司藥品研發能力和範圍,一定程度上節約了公司研發成本,分攤研發風險;且合同均以標的藥品達到與原研藥品的質量和療效一致,最終獲得藥品註冊批件為目標,將對公司產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.